Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Lenvatinib plus TACE-HAIC in HCC (PLATIC)
NCT04814043Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04814043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814043.